<- Go home

Added to YB: 2026-08-14

Pitch date: 2026-08-11

AQST [bullish]

Aquestive Therapeutics, Inc.

-0.47%

current return

Author Info

No bio for this author

Company Info

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Market Cap

$530.9M

Pitch Price

$4.27

Price Target

6.50 (+53%)

Dividend

N/A

EV/EBITDA

-9.77

P/E

-6.50

EV/Sales

9.09

Sector

Pharmaceuticals

Category

special_situation

Show full summary:
I'm up 20% in 2 weeks on this unknown pharma stock: The best is yet to come (50% upside) - $AQST

AQST: Epinephrine oral film (Anaphylm) rejected by FDA Jan 2026 only on packaging/human-factors, no efficacy/safety/mfg issues. Aug redesign cut pouch-open to 3s, placement errors -80%. Analysis of 21 similar rejections: single-fix cases approved in ~14mo. Author sees 80% approval odds, ~$6.50 by spring 2027 vs $4.29 now (50% priced in); $2.25 downside floor. $540M cap.

Read full article (10 min)